319 related articles for article (PubMed ID: 19854495)
1. Epigenetic therapies for chemoresensitization of epithelial ovarian cancer.
Matei DE; Nephew KP
Gynecol Oncol; 2010 Feb; 116(2):195-201. PubMed ID: 19854495
[TBL] [Abstract][Full Text] [Related]
2. Epigenomics and ovarian carcinoma.
Maldonado L; Hoque MO
Biomark Med; 2010 Aug; 4(4):543-70. PubMed ID: 20701443
[TBL] [Abstract][Full Text] [Related]
3. Epigenetic mechanisms and therapeutic targets of chemotherapy resistance in epithelial ovarian cancer.
Borley J; Brown R
Ann Med; 2015; 47(5):359-69. PubMed ID: 26158617
[TBL] [Abstract][Full Text] [Related]
4. Tackling drug resistance in ovarian cancer with epigenetic targeted drugs.
Zhao L; Guo H; Chen X; Zhang W; He Q; Ding L; Yang B
Eur J Pharmacol; 2022 Jul; 927():175071. PubMed ID: 35636522
[TBL] [Abstract][Full Text] [Related]
5. Genome-wide methylation profiling of ovarian cancer patient-derived xenografts treated with the demethylating agent decitabine identifies novel epigenetically regulated genes and pathways.
Tomar T; de Jong S; Alkema NG; Hoekman RL; Meersma GJ; Klip HG; van der Zee AG; Wisman GB
Genome Med; 2016 Oct; 8(1):107. PubMed ID: 27765068
[TBL] [Abstract][Full Text] [Related]
6. Epigenetic therapy for ovarian cancer: promise and progress.
Moufarrij S; Dandapani M; Arthofer E; Gomez S; Srivastava A; Lopez-Acevedo M; Villagra A; Chiappinelli KB
Clin Epigenetics; 2019 Jan; 11(1):7. PubMed ID: 30646939
[TBL] [Abstract][Full Text] [Related]
7. Epigenetics in ovarian cancer.
Seeber LM; van Diest PJ
Methods Mol Biol; 2012; 863():253-69. PubMed ID: 22359298
[TBL] [Abstract][Full Text] [Related]
8. Epigenetic Pathways Offer Targets for Ovarian Cancer Treatment.
Gyparaki MT; Papavassiliou AG
Clin Breast Cancer; 2018 Jun; 18(3):189-191. PubMed ID: 29042129
[No Abstract] [Full Text] [Related]
9. Targeting the epigenome in ovarian cancer.
Murphy SK
Future Oncol; 2012 Feb; 8(2):151-64. PubMed ID: 22335580
[TBL] [Abstract][Full Text] [Related]
10. MiR-152 and miR-185 co-contribute to ovarian cancer cells cisplatin sensitivity by targeting DNMT1 directly: a novel epigenetic therapy independent of decitabine.
Xiang Y; Ma N; Wang D; Zhang Y; Zhou J; Wu G; Zhao R; Huang H; Wang X; Qiao Y; Li F; Han D; Wang L; Zhang G; Gao X
Oncogene; 2014 Jan; 33(3):378-86. PubMed ID: 23318422
[TBL] [Abstract][Full Text] [Related]
11. DNA hypomethylation-mediated activation of Cancer/Testis Antigen 45 (CT45) genes is associated with disease progression and reduced survival in epithelial ovarian cancer.
Zhang W; Barger CJ; Link PA; Mhawech-Fauceglia P; Miller A; Akers SN; Odunsi K; Karpf AR
Epigenetics; 2015; 10(8):736-48. PubMed ID: 26098711
[TBL] [Abstract][Full Text] [Related]
12. Developmental DNA methyltransferase inhibitors in the treatment of gynecologic cancers.
Duenas-Gonzalez A; Medina-Franco JL; Chavez-Blanco A; Dominguez-Gomez G; Fernández-de Gortari E
Expert Opin Pharmacother; 2016; 17(3):323-38. PubMed ID: 26559668
[TBL] [Abstract][Full Text] [Related]
13. Evaluation of Epigenetic Drug Targeting of Heterogenous Tumor Cell Fractions Using Potential Biomarkers of Response in Ovarian Cancer.
Singh AK; Chandra N; Bapat SA
Clin Cancer Res; 2015 Nov; 21(22):5151-63. PubMed ID: 26130461
[TBL] [Abstract][Full Text] [Related]
14. An Effective Epigenetic-PARP Inhibitor Combination Therapy for Breast and Ovarian Cancers Independent of BRCA Mutations.
Pulliam N; Fang F; Ozes AR; Tang J; Adewuyi A; Keer H; Lyons J; Baylin SB; Matei D; Nakshatri H; Rassool FV; Miller KD; Nephew KP
Clin Cancer Res; 2018 Jul; 24(13):3163-3175. PubMed ID: 29615458
[No Abstract] [Full Text] [Related]
15. Minireview: epigenetic changes in ovarian cancer.
Balch C; Fang F; Matei DE; Huang TH; Nephew KP
Endocrinology; 2009 Sep; 150(9):4003-11. PubMed ID: 19574400
[TBL] [Abstract][Full Text] [Related]
16. Involvement of epigenetic modification of TERT promoter in response to all-trans retinoic acid in ovarian cancer cell lines.
Losi L; Lauriola A; Tazzioli E; Gozzi G; Scurani L; D'Arca D; Benhattar J
J Ovarian Res; 2019 Jul; 12(1):62. PubMed ID: 31291979
[TBL] [Abstract][Full Text] [Related]
17. Epigenetic silencing of HSulf-1 in ovarian cancer:implications in chemoresistance.
Staub J; Chien J; Pan Y; Qian X; Narita K; Aletti G; Scheerer M; Roberts LR; Molina J; Shridhar V
Oncogene; 2007 Jul; 26(34):4969-78. PubMed ID: 17310998
[TBL] [Abstract][Full Text] [Related]
18. The Epigenetic Landscape in the Treatment of Gynecologic Malignancies.
Eskander RN
Am Soc Clin Oncol Educ Book; 2018 May; 38():480-487. PubMed ID: 30231335
[TBL] [Abstract][Full Text] [Related]
19. Overcoming immune suppression with epigenetic modification in ovarian cancer.
McCaw TR; Randall TD; Arend RC
Transl Res; 2019 Feb; 204():31-38. PubMed ID: 30048638
[TBL] [Abstract][Full Text] [Related]
20. Epigenetic regulation of CD133 and tumorigenicity of CD133+ ovarian cancer cells.
Baba T; Convery PA; Matsumura N; Whitaker RS; Kondoh E; Perry T; Huang Z; Bentley RC; Mori S; Fujii S; Marks JR; Berchuck A; Murphy SK
Oncogene; 2009 Jan; 28(2):209-18. PubMed ID: 18836486
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
